Wen Sun1, Yan Sheng1, Yu Weng2, Chun-Xiao Xu3, Susan E I Williams4, Yu-Tao Liu5, Michael A Hauser6, R Rand Allingham6, Ming-Juan Jin3, Guang-Di Chen3. 1. Department of Ophthalmology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, China. 2. Department of Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, Zhejiang Province, China. 3. Department of Public Health, Zhejiang University School of Medicine, Hangzhou 310058, Zhejiang Province, China. 4. Division of Ophthalmology, Department of Neurosciences, University of the Witwatersrand, Johannesburg 2050, South Africa. 5. Center for Human Genetics, Duke University Medical Center, Durham, North Carolina 27710, USA. 6. Center for Human Genetics, Duke University Medical Center, Durham, North Carolina 27710, USA ; Department of Ophthalmology, Duke University Eye Center, Durham, North Carolina 27710, USA.
Abstract
AIM: To study the associations between lysyl oxidase-like 1 (LOXL1) polymorphisms and primary open angle glaucoma (POAG) remain inconsistent. In this study, we have performed a meta-analysis to investigate the association of LOXL1 polymorphisms with POAG risk. METHODS: Published literature from PubMed and other databases were retrieved. All studies evaluating the association between LOXL1 polymorphisms (rs2165241, rs1048661, rs3825942) and POAG risk were included. Pooled odds ratio (OR) and 95% confidence interval (CI) were calculated using random- or fixed-effects model. RESULTS: Twelve studies were identified as eligible articles, with thirteen (2098 cases and 16 473 controls), thirteen (1795 cases and 2916 controls) and sixteen population cohorts (2456 cases and 2846 controls) for the association of rs2165241, rs1048661 and rs3825942 with POAG risk respectively. Overall analyses showed no association between each LOXL1 polymorphism and POAG risk, and the negative associations were remained when the subjects were stratified as Caucasian and Asian. The heterozygote of rs2165241 was associated with reduced POAG risk in hospital-based populations (TC vs CC: OR, 0.79, 95%CI: 0.63-0.99), and rs1048661 was associated with increased POAG risk in hospital-based populations in a dominant model (TT vs CC+CT: OR, 1.23, 95%CI: 1.01-1.50); however, these associations were not found in population-based subjects. CONCLUSION: This meta-analysis suggests that LOXL1 polymorphisms are not associated with POAG risk. Given the limited sample size, the associations of LOXL1 polymorphisms with POAG risk in hospital-based populations await further investigation.
AIM: To study the associations between lysyl oxidase-like 1 (LOXL1) polymorphisms and primary open angle glaucoma (POAG) remain inconsistent. In this study, we have performed a meta-analysis to investigate the association of LOXL1 polymorphisms with POAG risk. METHODS: Published literature from PubMed and other databases were retrieved. All studies evaluating the association between LOXL1 polymorphisms (rs2165241, rs1048661, rs3825942) and POAG risk were included. Pooled odds ratio (OR) and 95% confidence interval (CI) were calculated using random- or fixed-effects model. RESULTS: Twelve studies were identified as eligible articles, with thirteen (2098 cases and 16 473 controls), thirteen (1795 cases and 2916 controls) and sixteen population cohorts (2456 cases and 2846 controls) for the association of rs2165241, rs1048661 and rs3825942 with POAG risk respectively. Overall analyses showed no association between each LOXL1 polymorphism and POAG risk, and the negative associations were remained when the subjects were stratified as Caucasian and Asian. The heterozygote of rs2165241 was associated with reduced POAG risk in hospital-based populations (TC vs CC: OR, 0.79, 95%CI: 0.63-0.99), and rs1048661 was associated with increased POAG risk in hospital-based populations in a dominant model (TT vs CC+CT: OR, 1.23, 95%CI: 1.01-1.50); however, these associations were not found in population-based subjects. CONCLUSION: This meta-analysis suggests that LOXL1 polymorphisms are not associated with POAG risk. Given the limited sample size, the associations of LOXL1 polymorphisms with POAG risk in hospital-based populations await further investigation.
Authors: Laetitia Thomassin; Claudio C Werneck; Thomas J Broekelmann; Claudine Gleyzal; Ian K Hornstra; Robert P Mecham; Pascal Sommer Journal: J Biol Chem Date: 2005-10-26 Impact factor: 5.157
Authors: Janey L Wiggs; Basil Pawlyk; Edward Connolly; Michael Adamian; Joan W Miller; Louis R Pasquale; Ramez I Haddadin; Cynthia L Grosskreutz; Douglas J Rhee; Tiansen Li Journal: Invest Ophthalmol Vis Sci Date: 2014-02-10 Impact factor: 4.799
Authors: Ursula Schlötzer-Schrehardt; Francesca Pasutto; Pascal Sommer; Ian Hornstra; Friedrich E Kruse; Gottfried O H Naumann; André Reis; Matthias Zenkel Journal: Am J Pathol Date: 2008-10-30 Impact factor: 4.307
Authors: Subhabrata Chakrabarti; Kollu Nageswara Rao; Inderjeet Kaur; Rajul S Parikh; Anil K Mandal; Garudadri Chandrasekhar; Ravi Thomas Journal: Invest Ophthalmol Vis Sci Date: 2008-01-25 Impact factor: 4.799